"The discussion highlights a perceived undervaluation of the stock $EV, with participants suggesting that it warrants more attention due to its potential in comparison to Biovica, which offers similar tests at a lower cost. Concerns about the lack of awareness and engagement among investors are also noted, indicating a need for increased dialogue around the stock's prospects."